The Endocarditis drugs in development market research report provides comprehensive information on the therapeutics under development for Endocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Endocarditis. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Endocarditis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Endocarditis and features dormant and discontinued products.

GlobalData tracks five drugs in development for Endocarditis by five companies/universities/institutes. The top development phase for Endocarditis is preclinical with four drugs in that stage. The Endocarditis pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Endocarditis pipeline products market are: PHAXIAM Therapeutics, iNtRON Biotechnology and Arietis.

The key targets in the Endocarditis pipeline products market include Penicillin Binding Protein (PBP), ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial (Endopeptidase Clp or CLPP or EC, and Bacterial Cell Wall.

The key mechanisms of action in the Endocarditis pipeline product include Penicillin Binding Protein (PBP) Inhibitor with one drug in Preclinical. The Endocarditis pipeline products include three routes of administration with the top ROA being Intravenous and four key molecule types in the Endocarditis pipeline products market including Small Molecule, and Biologic.

Endocarditis overview

Endocarditis is a rare, life-threatening inflammatory condition that occurs when the inner lining of the heart’s chambers and valves become infected. It is usually caused by bacterial infection, and rarely by fungus. Symptoms include high temperature, chills, night sweats, headaches, shortness of breath, cough, fatigue, muscle and joint pain, heart murmur, and pale skin. Blood culture tests, CBC, CRP, ESR, and echocardiogram are used as diagnostics. Treatment includes antibiotic therapy.

For a complete picture of Endocarditis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.